e-ore's sleepers

[e-ore]

MLPH - What's coming to the USA, this and other ThermaLIFE products bold type is my emphasis):

Thermalife Cream – The first in a new class of topical arthritic pain relief in pharmacy. Thermalife Cream with it's unique patented peptide formula using naturally-derived ingredients represents a new class in topical pain relief for muscular and arthritic pain. As a result it is becoming increasingly popular in pharmacy(1). Peptides are chains of amino acids which in Thermalife, act on the body’s pain pathway system to impact chemical signals to and from the brain to the site of pain. In a double-blind study of the product in the treatment of osteoarthritis, Thermalife demonstrated significant difference in pain, movement and morning function after two weeks of treatment, compared to no significant difference with placebo(2). In a consumer self-assessment Survey involving over 200 users, 89% reported getting pain relief in 30 minutes or less, and on ‘what level of pain relief they received’, 79% reported either “totally” or “mostly”(3).
• Thermalife is a well-tolerated cream formulation,suitable to apply day and night
• Thermalife has a very mild non-invasive smell
• Thermalife is non-greasy and stain-free
• Thermalife does not contain heatgenerating or synthetic active ingredients
• Thermalife does not have duration of use limitations (unlike NSAIDS), and may be used 3 x a day as needed.
For more information about Thermalife Cream and to enquire about samples, please contact Renee Greenwell,
Marketing Manager, Thermalife International Pharmaceuticals Pty Ltd, 284 Oxford Street,
Leederville, Western Australia, 6007.
Phone + 61 8 9443 3433 or visit the website:
www.thermalife.com.au

References
(1).IMS data on file. (2).Edelman J. Double-Blind Trial of Peptophen in the Treatment of Osteoarthritis. (3).Australian Masters Games
Survey, 2011.

http://www.psa.org.au/download/ap/apjan13/Business-and-industry-news.pdf

"Molecular Pharmacology Pty Ltd (a wholly-owned and subsidiary of MPL (USA)) executed an agreement with Dermatology Development Corp. (DDC) of New York USA to broker deals with third party entities to introduce both Thermalife® Cream and Nutracel derivatives into the US, predominantly in dermatological applications. This represents a major move by the Company to establish the technology in the US and to open a new area of operations into the dermatological field.
Our research findings particularly in the area of inflammation have immediate utility in areas such as psoriasis, atopic dermatitis and other inflammatory skin conditions and DDC is well placed to ensure we have access to strong partnerships."

http://www.aspecthuntley.com.au/asxdata/20130731/pdf/01429819.pdf

http://www.sec.gov/Archives/edgar/data/1191357/000122150813000009/agmjuly2013.htm

Products to be introduced in the US:

Products
(a) THERMALIFE CREAM
(b) THERMALIFE ACTIVE GEL
(c) THERMALIFE AFTER SUN GEL
(d) THERMALIFE SPRAY
(e) THERMALIFE HAND LOTION
(f) THERMALIFE COSMETICS

Technology
(a) Nutracel
(b) Nutracel T
(c) Nutracel P
(d) Combinations of Nutracel and various approved naturally derived and synthetic ingredients
(e) Nutracel based cosmetic formulations for skin care / moisturization
(f) Nutracel based cosmeceuticals - skin soothing, anti-wrinkle, skin tone evening and other cosmetic endpoints to be defined as an outcome of this contract.
(g) Nutracel based topical creams and gels for atopic dermatitis, psoriasis, inflammatory skin conditions, acne and other indications to be defined as an outcome of this contract